CD274 and melanoma: To understand how the pre-existing immune contexture of stage III melanoma might influence prognosis, Madore et al. 20 investigated PD-L1 by IHC, and correlated this with tumor non-synonymous mutation (NSM) burden, immune gene expression data and clinical outcome.